The advantage of $OCAT embryonic ESC is that it can be off-the-shelf and ready to go for all. HOWEVER it can only be used for immune-privileged sites such as parts of the eye and certain parts of the Central Nervous System.
The advantage for autologous ASCs is that they are specific and no rejection chemicals are required as they are donor-to patient identical. The disadvantage for ASC is that they take upwards of 10 to 12 days to prepare for the specific patient receiving their own ASC. VCEL specializes in ASC from bone-marrow with their Patented bioreactors and other IP Patents. $OCAT IMO will also be specializing in certain ASC with their IPSC Patented IPs.
News 
Market Data 
Discover 
AI
